Device Industry Veterans Join Benvenue Medical Board of Directors

SANTA CLARA, Calif., May 21, 2012 /PRNewswire via COMTEX/ — Benvenue Medical, Inc., a developer of minimally invasive solutions for spine repair, announced today the appointments of two new members to its Board of Directors. Thomas M. Prescott, president and CEO of Align Technology, Inc., and Thomas C. Wilder, president and CEO of Sequent Medical, Inc., are both experienced at bringing innovative medical technologies to the global marketplace.
“We welcome the additional experience and leadership that both Tom Prescott and Tom Wilder bring to our already high-caliber board, and we look forward to the new insights they’ll provide for our continued rapid growth and global product commercialization,” said Robert Weigle, CEO of Benvenue Medical. “Our vision is to become a leading company with product platforms in multiple markets in spine repair.” Benvenue Medical has entered a $9 billion global spinal device market with three breakthrough minimally invasive products to treat degenerative disc disease (DDD) and vertebral compression fractures (VCFs).
Tom Prescott was also elected chairman of the board. Tom has been president and CEO of Align Technology, Inc., since 2002. The company is the inventor of Invisalign and an innovator in digital dentistry, and it has grown significantly under his leadership. Invisalign has become the global leader in clear aligner therapy with expanding clinical adoption and powerful consumer brand recognition. Previously, Mr. Prescott was president and CEO of Cardiac Pathways, where he successfully led a turnaround prior to its acquisition by Boston Scientific. Prior to Cardiac Pathways, Mr. Prescott held various sales, marketing, management and executive roles at Nellcor Puritan Bennett, GE Medical Systems, and Siemens. Tom holds a Master of Management from the Kellogg Graduate School of Management at Northwestern University and a bachelor’s degree, with emphasis in Civil Engineering, from Arizona State University.
Tom Wilder has served as the president and CEO of Sequent Medical, Inc., a privately held medical device company focused on developing innovative devices for the treatment of neurovascular disease, since 2010. Prior to joining Sequent Medical, Mr. Wilder was president and CEO of Photothera, a private company developing transcranial laser therapy for the treatment of acute ischemic stroke. Prior to Photothera, Mr. Wilder was president and CEO of Micro Therapeutics, a publicly traded company that provided a broad range of advanced interventional products to neurovascular specialists. Micro Therapeutics was merged into ev3 in January 2006. Prior to Micro Therapeutics, Mr. Wilder held several management positions during an 11-year tenure at Medtronic, Inc. Tom holds a Master of Management from the Kellogg Graduate School of Management at Northwestern University, and a BA in Economics from Stanford University. He also serves on the Board of Endologix, Inc.